48P A retrospective, observational study of telomerase peptide immunotherapy in heavily treated solid cancer patients
ConclusionIn conclusion, riavex as an anti-cancer vaccine is relatively safe in heavily pre-treated solid cancer patients and is assessed to improve quality of life, although the treatment response is not promising.Legal entity responsible for the studyThe author.FundingHas not received any funding.DisclosureThe author has declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Vaccines | Carcinoma | Emergency Medicine | Immunotherapy | Kidney Cancer | Legislation | Renal Cell Carcinoma | Study | Vaccines